Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery

Study Overview
=================
Brief Summary
-----------------
Intramuscular versus intravenous prophylactic oxytocin for the third stage of labour following vaginal delivery: A randomised controlled trial

Detailed Description
-----------------
Prevention of postpartum haemorrhage is essential in the pursuit of improved health care for women. In this study investigators aimed to compare intramuscular oxytocin with intravenous oxytocin for the routine prevention of postpartum haemorrhage in women who deliver vaginally.In some countries, intravenous access can not be provided easily . Intramuscular application is faster , easier and tougher enforcement requires less skill and equipment . For this reason, less educated , which can be applied by those offering health services .

Official Title
-----------------
Intramuscular Versus Intravenous Prophylactic Oxytocin for the Third Stage of Labour Following Vaginal Delivery: A Randomised Controlled Trial

Conditions
-----------------
Postpartum Hemorrhage

Intervention / Treatment
-----------------
* Drug: intarvenous and intramusculer 10 IU oxytocin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Research volunteers, the undersigned, pregnant women Only with vaginal delivery (episiotomy and perineal tears can) > 34 weeks or more will be Cephalic presentation will be At low risk of postpartum hemorrhage Exclusion Criteria: <18 years Multiple pregnancies The presence of uterine myoma Having postpartum hemorrhage in previous pregnancies Placenta previa, polyhydramnios More than four parity Fetal macrosomia Hb <9mg/dl preeclampsia Uterine anomalies Receiving anticoagulant therapy, suspected coagulopathy > 42 weeks of pregnancy Oxytocin allergy -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: intravenous 10 ıu oxytocin<br>group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery | Drug: intarvenous and intramusculer 10 IU oxytocin<br>* intarvenous and intramusculer 10 IU oxytocin<br>|
| Experimental: intramusculer 10 ıu oxytocin<br>group which oxytocin administered intramusculary after vaginal delivery | Drug: intarvenous and intramusculer 10 IU oxytocin<br>* intarvenous and intramusculer 10 IU oxytocin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| early postpartum hemorrhage | Blood loss during the birth and postpartum hemorrhage asset (within 24 hours> 500 cc blood loss) | postpartum 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood transfusion requirement | Blood transfusion requirement duration of phase 3 (> 30 min) necessity of additional treatments for postpartum hemorrhage the necessity of manual removal of placenta side effects of the | postpartum 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prophylactic, postpartum hemorrhage, oxytocin, vaginal delivery